We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 61-67 of 67 Articles
Dan Merenstein, MD
I must have won. That is what everyone tells me. At the beginning there were a few telephone calls, followed by e-mails, and now every talk I give someone brings up how happy I must feel for winning. What I purportedly won was the new recommendations against routine checking for ...
Original Investigation 
Inmaculada Hernandez, PharmD; Seo Hyon Baik, PhD; Antonio Piñera, MD; Yuting Zhang, PhD
Includes: Supplemental Content

Importance  It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice.

Objective  To compare the risk of bleeding associated with dabigatran and warfarin using Medicare data.

Design, Setting, and Participants  In this retrospective cohort ...

Original Investigation 
David A. Cook, MD, MHPE; Eric S. Holmboe, MD; Kristi J. Sorensen, MSEd; Richard A. Berger, MD, PhD; John M. Wilkinson, MD
Includes: Supplemental Content

Importance  Despite general support for the goals of maintenance of certification (MOC), concerns have been raised about its effectiveness, relevance, and value.

Objective  To identify barriers and enabling features associated with MOC and how MOC can be changed to better accomplish its intended purposes.

Design, Setting, ...

Editor's Note 
Rita F. Redberg, MD, MSc
Dabigatran was approved by the Food and Drug Administration (FDA) in 2010 via the accelerated pathway after a 6-month review. The haste to approve novel drugs places an increasing importance on postapproval data to help better understand risks and benefits. Thus, the postapproval data on the use of dabigatran in ...
Special Communication 
Daniel J. Morgan, MD, MS; Scott M. Wright, MD; Sanket Dhruva, MD
Includes: Supplemental Content

Importance  Overuse of medical care, consisting primarily of overdiagnosis and overtreatment, is a common clinical problem.

Objective  To identify and highlight the most significant clinical articles published in 2013 related to medical overuse.

Evidence Review  A systematic review of English-language articles published in 2013 that ...

Research Letter 
Christina Nelson, MD, MPH; Sarah Elmendorf, MD; Paul Mead, MD, MPH
Clinical features of Lyme disease include erythema migrans rash, facial palsy, arthritis, and peripheral neuropathy. In endemic areas, patients with erythema migrans can be diagnosed clinically. Otherwise, diagnosis is based on the history of possible exposure, compatible clinical features, and positive 2-tier serologic testing.1
Viewpoint  FREE
Michael T. Osterholm, PhD, MPH; Kristine A. Moore, MD, MPH; Lawrence O. Gostin, JD
This Viewpoint discusses several key public health lessons learned from the current West Africa Ebola epidemic that are changing the way we think about emerging infectious disease threats.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal